rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis

Sandeep Negi(Johns Hopkins Medicine), Patrick A. Brown(Haemonetics (United States))

Oncotarget

June 5, 2015

10.18632/oncotarget.4093

Cited by 96

Related Papers

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

|JAMA|2021|358

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in <i>KMT2A</i>-rearranged leukemia

|Blood|2021|113

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)

|Pediatric Blood & Cancer|2017|73

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children

|European Journal of Cancer|2020|25